A Dual-Wall 3D-Printed Anti-tampering Medical Bottle

[1]  S. Vosburg,et al.  A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. , 2013, Addiction.

[2]  D. Fiellin,et al.  Abuse-Deterrent Opioid Formulations - Putting the Potential Benefits into Perspective. , 2017, The New England journal of medicine.

[3]  F. Johnson,et al.  Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability. , 2011, Pain physician.

[4]  L. Paulozzi,et al.  Decline in Drug Overdose Deaths After State Policy Changes — Florida, 2010–2012 , 2014, MMWR. Morbidity and mortality weekly report.

[5]  S. Vosburg,et al.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. , 2012, Drug and alcohol dependence.

[6]  S. Butler,et al.  Abuse risks and routes of administration of different prescription opioid compounds and formulations , 2011, Harm reduction journal.

[7]  Nathaniel Katz,et al.  Tampering with Prescription Opioids: Nature and Extent of the Problem, Health Consequences, and Solutions , 2011, The American journal of drug and alcohol abuse.

[8]  H. Chilcoat,et al.  Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation† , 2014, Pharmacoepidemiology and drug safety.

[9]  Laura Bix,et al.  User-pack interaction: Insights for Designing Inclusive Child-resistant Packaging , 2010 .

[10]  M. Sapiano,et al.  Notes from the Field: Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion - United States, 2008-2015. , 2016, MMWR. Morbidity and mortality weekly report.

[11]  Edward J Cone,et al.  An iterative model for in vitro laboratory assessment of tamper deterrent formulations. , 2013, Drug and alcohol dependence.

[12]  R. Raffa,et al.  Opioid Formulations Designed to Resist/Deter Abuse , 2010, Drugs.